{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:01:33Z","timestamp":1758632493049,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000679","81930120"],"award-info":[{"award-number":["82000679","81930120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Over half of the patients with hepatitis B virus associated membranous nephropathy (HBV-MN) were found to be phospholipase A2 receptor (PLA2R) positive. Whether MN is really secondary to hepatitis B or just coincidence of hepatitis and PLA2R positive idiopathic MN (IMN) remains controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively studied seven PLA2R positive HBV-MN patients with complete data in Huashan Hospital from 2009 to 2016 and compared them with PLA2R positive idiopathic MN patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Proteinuria and renal function of these 7 HBV-MN patients were similar to that of IMN patients. However, 5 of them were female and half showed hypocomplementemia, while in IMN group only 32.4% were female and 20% had hypocomplementemia, and the level of hematuria was 94.5\/\u03bcL in HBV-MN patients and 64.9 \/\u03bcL in IMN patients, though there was no statistically significant difference. Renal biopsies revealed significantly increased mesangial eletron-deposits in HBV-MN patients. All 7 patients received antiviral therapy, and one patient received immunosuppresants due to severe nephrotic syndrome with acute myocardial infarction and elevated serum creatinine. Compared with IMN group, the prevalence of remission without immunosuppressive therapy of HBV-MN patients was higher (85.7% vs. 43.7%), while the percentage of patients receiving immunosuppresants was lower (14.3% vs. 47.9%) (<jats:italic>P<\/jats:italic>=0.048).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with IMN patients, PLA2R positive HBV-MN patients had a more favorable prognosis after antiviral therapy, indicating a secondary form of MN. For these patients, antiviral treatment is recommended and long observation time should be provided before use of immunosuppressive treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02871-y","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T13:03:13Z","timestamp":1657544593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Favorable outcome in PLA2R positive HBV-associated membranous nephropathy"],"prefix":"10.1186","volume":"23","author":[{"given":"Ruiying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qionghong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"issue":"12","key":"2871_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"issue":"10003","key":"2871_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546\u201355.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2871_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","volume":"71","author":"J Xiao","year":"2019","unstructured":"Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol. 2019;71(1):212\u201321.","journal-title":"J Hepatol"},{"issue":"5","key":"2871_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.ackd.2015.06.003","volume":"22","author":"A Gupta","year":"2015","unstructured":"Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis. 2015;22(5):343\u201351.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"2871_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000077065","volume":"24","author":"R Bhimma","year":"2004","unstructured":"Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004;24(2):198\u2013211.","journal-title":"Am J Nephrol"},{"issue":"1","key":"2871_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"2871_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/modpathol.2012.207","volume":"26","author":"CP Larsen","year":"2013","unstructured":"Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26(5):709\u201315.","journal-title":"Mod Pathol"},{"issue":"4\u20135","key":"2871_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000431331","volume":"41","author":"Q Xie","year":"2015","unstructured":"Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Ame J Nephrol. 2015;41(4\u20135):345\u201353.","journal-title":"Ame J Nephrol"},{"key":"2871_CR9","first-page":"270","volume":"04","author":"WZ Zou","year":"2001","unstructured":"Zou WZ. Guidence on the diagnosis of renal disease basing on histopathological examination. Chin J Nephrol. 2001;04:270\u20135.","journal-title":"Chin J Nephrol."},{"issue":"2","key":"2871_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ekir.2017.09.009","volume":"3","author":"L Berchtold","year":"2018","unstructured":"Berchtold L, Zanetta G, Dahan K, Mihout F, Peltier J, Guerrot D, et al. Efficacy and safety of rituximab in hepatitis B virus-associated PLA2R-positive membranous nephropathy. Kidney Int Rep. 2018;3(2):486\u201391.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2871_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.1995.27","volume":"47","author":"CY Lin","year":"1995","unstructured":"Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int. 1995;47(1):225\u201330.","journal-title":"Kidney Int"},{"issue":"4","key":"2871_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3904\/kjim.2012.27.4.411","volume":"27","author":"IO Sun","year":"2012","unstructured":"Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med. 2012;27(4):411\u20136.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"2871_CR13","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S, Lai FMM, Lui YH, Tang CSO, Kung NNS, Ho YW, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int. 2005;68(4):1750\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"2871_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/0016-5085(95)90343-7","volume":"109","author":"HS Conjeevaram","year":"1995","unstructured":"Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology. 1995;109(2):540\u20136.","journal-title":"Gastroenterology"},{"issue":"1","key":"2871_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000185802","volume":"54","author":"KN Lai","year":"1990","unstructured":"Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron. 1990;54(1):12\u20137.","journal-title":"Nephron"},{"issue":"6","key":"2871_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3748\/wjg.v16.i6.770","volume":"16","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. World J Gastroenterol. 2010;16(6):770\u20137.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"2871_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3748\/wjg.v18.i8.821","volume":"18","author":"XY Zheng","year":"2012","unstructured":"Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol. 2012;18(8):821\u201332.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2871_CR18","first-page":"1593","volume":"8","author":"L Wang","year":"2016","unstructured":"Wang L, Ye Z, Liang H, Zhang B, Xu L, Feng Z, et al. The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication. American J Trans Res. 2016;8(3):1593\u2013600.","journal-title":"American J Trans Res"},{"key":"2871_CR19","doi-asserted-by":"crossref","unstructured":"Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement.\u00a0Liver Int.\u00a02018;38(1):23\u201332.","DOI":"10.1111\/liv.13498"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02871-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T13:03:31Z","timestamp":1657544611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02871-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02871-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by ethic committee of Huashan Hospital, Fudan University (KY2016-394). All methods were performed in accordance with the relevant guidelines and regulations. Informed consent has been obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}